GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alder BioPharmaceuticals Inc (NAS:ALDR) » Definitions » Piotroski F-Score

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Piotroski F-Score : 0 (As of May. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Alder BioPharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alder BioPharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Alder BioPharmaceuticals's Piotroski F-Score or its related term are showing as below:


Alder BioPharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Alder BioPharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alder BioPharmaceuticals Piotroski F-Score Chart

Alder BioPharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Piotroski F-Score
Get a 7-Day Free Trial 5.00 3.00 3.00 3.00 2.00

Alder BioPharmaceuticals Quarterly Data
Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 2.00 3.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun19) TTM:Last Year (Jun18) TTM:
Net Income was -60.92 + -80.089 + -117.934 + -58.411 = $-317.35 Mil.
Cash Flow from Operations was -51.474 + -72.85 + -74.576 + -59.298 = $-258.20 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Jun18)
to the end of this year (Jun19) was
(548.35 + 496.753 + 426.239 + 513.168 + 462.567) / 5 = $489.4154 Mil.
Total Assets at the begining of this year (Jun18) was $548.35 Mil.
Long-Term Debt & Capital Lease Obligation was $192.38 Mil.
Total Current Assets was $451.67 Mil.
Total Current Liabilities was $50.53 Mil.
Net Income was -59.565 + -54.357 + -87.031 + -68.389 = $-269.34 Mil.

Revenue was 0 + 0.936 + 0 + 0 = $0.94 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Jun17)
to the end of last year (Jun18) was
(253.968 + 366.314 + 303.136 + 599.413 + 548.35) / 5 = $414.2362 Mil.
Total Assets at the begining of last year (Jun17) was $253.97 Mil.
Long-Term Debt & Capital Lease Obligation was $176.05 Mil.
Total Current Assets was $321.21 Mil.
Total Current Liabilities was $29.54 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alder BioPharmaceuticals's current Net Income (TTM) was -317.35. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alder BioPharmaceuticals's current Cash Flow from Operations (TTM) was -258.20. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun18)
=-317.354/548.35
=-0.5787435

ROA (Last Year)=Net Income/Total Assets (Jun17)
=-269.342/253.968
=-1.06053519

Alder BioPharmaceuticals's return on assets of this year was -0.5787435. Alder BioPharmaceuticals's return on assets of last year was -1.06053519. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Alder BioPharmaceuticals's current Net Income (TTM) was -317.35. Alder BioPharmaceuticals's current Cash Flow from Operations (TTM) was -258.20. ==> -258.20 > -317.35 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun18 to Jun19
=192.384/489.4154
=0.39308939

Gearing (Last Year: Jun18)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun17 to Jun18
=176.052/414.2362
=0.4250039

Alder BioPharmaceuticals's gearing of this year was 0.39308939. Alder BioPharmaceuticals's gearing of last year was 0.4250039. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun19)=Total Current Assets/Total Current Liabilities
=451.672/50.529
=8.93886679

Current Ratio (Last Year: Jun18)=Total Current Assets/Total Current Liabilities
=321.205/29.537
=10.87466567

Alder BioPharmaceuticals's current ratio of this year was 8.93886679. Alder BioPharmaceuticals's current ratio of last year was 10.87466567. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Alder BioPharmaceuticals's number of shares in issue this year was 83.48. Alder BioPharmaceuticals's number of shares in issue last year was 67.966. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0.936
=0

Alder BioPharmaceuticals's gross margin of this year was . Alder BioPharmaceuticals's gross margin of last year was 0. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun18)
=0/548.35
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun17)
=0.936/253.968
=0.0036855

Alder BioPharmaceuticals's asset turnover of this year was 0. Alder BioPharmaceuticals's asset turnover of last year was 0.0036855. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alder BioPharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Alder BioPharmaceuticals  (NAS:ALDR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Alder BioPharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Alder BioPharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Alder BioPharmaceuticals (Alder BioPharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
11804 North Creek Parkway South, Bothell, WA, USA, 98011
Alder BioPharmaceuticals is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in two geographic regions: the United States and Australia. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.
Executives
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF
H Lundbeck A S 10 percent owner 9 OTTILIAVEJ DK 2500 VALBY, COPENHAGEN, DENMARK G7 00000
Clay B Siegall director 21823 30TH DR SE, BOTHELL WA 98021
Paul Streck officer: Chief Medical Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Wendy L Yarno director
Carlos Campoy officer: Chief Financial Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Robert Azelby director, officer: President and CEO 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Heather Preston director C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102
Jeremy Green director 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc director ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Paul B Cleveland director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Mark James Litton officer: Chief Business Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Eric G Carter officer: Interim Chief Medical Officer C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Headlines

From GuruFocus